Sign up to save your podcasts
Or
Share Episode 04: Toward in silico Lead Discovery – the Advent of AI and Machine Learning w/ Lars Linden, PhD, Head, Protein Biochemistry, Biologics Research, Bayer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 04: Toward in silico Lead Discovery – the Advent of AI and Machine Learning w/ Lars Linden, PhD, Head, Protein Biochemistry, Biologics Research, Bayer
Dr. Lars Linden will be presenting during the Optimisation & Developability conference at PEGS Europe Summit, November 18-22, in Lisbon, Portugal. He speaks with CHI on August 6, 2019 to share his current responsibilities and how they have and will continue to evolve, especially with AI and machine learning in the horizon.
Topics discussed include how developability assessments, combined with in silico assays and in vitro high throughput methods, are able to rank candidates quickly in discovery, to advance the best ones to lead optimization and help select the right molecules. This is especially useful with today’s myriad molecules from bi- to multi-specifics to different types of conjugates. Dr Linden further discusses the role and impact of AI and machine learning to accelerate and simplify drug discovery, and better predict and optimise molecules throughout the R&D value chain.
View all episodes
By Cambridge Healthtech Institute
4.8
2525 ratings
Dr. Lars Linden will be presenting during the Optimisation & Developability conference at PEGS Europe Summit, November 18-22, in Lisbon, Portugal. He speaks with CHI on August 6, 2019 to share his current responsibilities and how they have and will continue to evolve, especially with AI and machine learning in the horizon.
Topics discussed include how developability assessments, combined with in silico assays and in vitro high throughput methods, are able to rank candidates quickly in discovery, to advance the best ones to lead optimization and help select the right molecules. This is especially useful with today’s myriad molecules from bi- to multi-specifics to different types of conjugates. Dr Linden further discusses the role and impact of AI and machine learning to accelerate and simplify drug discovery, and better predict and optimise molecules throughout the R&D value chain.
More shows like The Chain: Protein Engineering Podcast
View all
Radiolab
43,812 Listeners
Freakonomics Radio
32,006 Listeners
Planet Money
30,695 Listeners
HBR IdeaCast
1,836 Listeners
The Daily
112,416 Listeners
The Long Run with Luke Timmerman
125 Listeners
The Indicator from Planet Money
9,529 Listeners
The Readout Loud
320 Listeners
The Journal.
6,093 Listeners
Fiction - Comedy Fiction
6,444 Listeners
Consider This from NPR
6,397 Listeners
BioCentury This Week
34 Listeners
Hard Fork
5,518 Listeners
Biotech Hangout
18 Listeners
The Top Line
13 Listeners